A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias


Por: Pérez-Amill, L, Armand-Ugón, M, Val-Casals, M, Martín-Herreros, B, Alamo, JR, Peña, S, Frigola, G, Altuna, A, Santos, C, Guijarro, F, Minguela, A, Bataller, A, Casanovas-Albertí, B, Uribe-Herranz, M, Navarro, I, Guerreiro, M, Sánchez-Martínez, D, Tirado, N, Velasco-Hernandez, T, Menéndez, P, Martínez, A, Rovira, M, Colomer, D, González-Navarro, EA, Esteve, J, Urbano-Ispizua, A, Montesinos, P, Delgado, J, Juan, ME and Klein-González, N

Publicada: 1 oct 2025 Ahead of Print: 1 ago 2025
Resumen:
Despite the remarkable clinical successes of chimeric antigen receptor (CAR) T-cell therapies in treating B-cell malignancies and multiple myeloma, similar outcomes have not been achieved in other indications. For patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL), treatment options are limited, yet CART-cell therapies offer significant potential to address this unmet need. Here, we introduce a first-in-class CART-cell therapy targeting CD84, a novel antigen, for the treatment of R/R AML and T-ALL. CD84 is highly expressed on leukemic blasts, with limited expression on hematopoietic stem progenitor cells (HSPC), and is largely absent in healthy human tissues. Our second-generation CARTs targeting CD84 (CART84) demonstrate potent cytotoxicity against AML and T-ALL cells both in vitro and in vivo in patient-derived xenograft (PDX) models. Furthermore, CART84 eliminated primary leukemic blasts while exhibiting low cytotoxicity against CD34+ HSPC in vitro and in humanized mouse models in vivo, suggesting a low risk of myelotoxicity. These results support CD84 as a promising target for AML and T-ALL and provide the foundation for our upcoming first-in-human phase I/II clinical trial using CD84-directed CAR T cell therapy for patients with R/R AML and T-ALL (EudraCT 2024-519966-31-00).

Filiaciones:
Pérez-Amill, L:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Gyala Therapeut SL, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Armand-Ugón, M:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Gyala Therapeut SL, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Val-Casals, M:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Martín-Herreros, B:
 Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain

 Inst Invest Sanitaria La Fe IIS La Fe, Hematol Res Grp, Valencia, Spain

Alamo, JR:
 Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain

Peña, S:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Gyala Therapeut SL, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Frigola, G:
 Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain

Altuna, A:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Univ Barcelona, Sch Med, Barcelona, Spain

Santos, C:
 Gyala Therapeut SL, Barcelona, Spain

Guijarro, F:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain

Minguela, A:
 Clin Univ Hosp Virgen Arrixaca HCUVA, Immunol Serv, Murcia, Spain

 Biomed Res Inst Murcia Pascual Parrilla IMIB PP, Murcia, Spain

Bataller, A:
 Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

 Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain

Casanovas-Albertí, B:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Uribe-Herranz, M:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Navarro, I:
 Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain

Guerreiro, M:
 Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain

 Inst Invest Sanitaria La Fe IIS La Fe, Hematol Res Grp, Valencia, Spain

Sánchez-Martínez, D:
 Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain

 Aragon Hlth Res Inst, Aragon ID Fdn, Zaragoza, Spain

Tirado, N:
 Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain

Velasco-Hernandez, T:
 Univ Barcelona, Sch Med, Barcelona, Spain

 Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain

:
 Univ Barcelona, Sch Med, Barcelona, Spain

 Univ Barcelona, Josep Carreras Leukemia Res Inst JCLRI, Sch Med, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain

 Pediat Canc Ctr Barcelona PCCB SJD, Inst Recerca Hosp St Joan De Deu, Barcelona, Spain

Martínez, A:
 Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain

Rovira, M:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

Colomer, D:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, CDB, Hematopathol Sect, Pathol Dept, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

González-Navarro, EA:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Esteve, J:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Sch Med, Barcelona, Spain

 Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

Urbano-Ispizua, A:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Sch Med, Barcelona, Spain

 Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

Montesinos, P:
 Hosp Univ & Politecn La Fe, Hematol Dept, Valencia, Spain

 Inst Invest Sanitaria La Fe IIS La Fe, Hematol Res Grp, Valencia, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Delgado, J:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Univ Barcelona, Sch Med, Barcelona, Spain

 Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

Juan, ME:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Univ Barcelona, Sch Med, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain

Klein-González, N:
 Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona, Spain

 Gyala Therapeut SL, Barcelona, Spain

 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Inst Salud Carlos III, Red Espanola Terapias Avanzadas TERAV, Madrid, Spain
ISSN: 08876924





Leukemia
Editorial
Nature Publishing Group, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 39 Número: 10
Páginas: 2432-2441
WOS Id: 001545916600001
ID de PubMed: 40770072
imagen Green Submitted, hybrid

MÉTRICAS